- Home
- PVL vs ATRA Comparison
PVL vs ATRA Comparison
Compare PVL & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVL
- ATRA
- Stock Information
- Founded
- PVL 2011
- ATRA 2012
- Country
- PVL United States
- ATRA United States
- Employees
- PVL N/A
- ATRA N/A
- Industry
- PVL Oil & Gas Production
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PVL Energy
- ATRA Health Care
- Exchange
- PVL Nasdaq
- ATRA Nasdaq
- Market Cap
- PVL 61.4M
- ATRA 40.1M
- IPO Year
- PVL N/A
- ATRA 2014
- Fundamental
- Price
- PVL $1.83
- ATRA $8.04
- Analyst Decision
- PVL
- ATRA Buy
- Analyst Count
- PVL 0
- ATRA 5
- Target Price
- PVL N/A
- ATRA $17.75
- AVG Volume (30 Days)
- PVL 124.2K
- ATRA 49.9K
- Earning Date
- PVL 01-01-0001
- ATRA 08-11-2025
- Dividend Yield
- PVL 5.14%
- ATRA N/A
- EPS Growth
- PVL N/A
- ATRA N/A
- EPS
- PVL 0.09
- ATRA N/A
- Revenue
- PVL $4,344,009.00
- ATRA $199,732,000.00
- Revenue This Year
- PVL N/A
- ATRA N/A
- Revenue Next Year
- PVL N/A
- ATRA N/A
- P/E Ratio
- PVL $21.70
- ATRA N/A
- Revenue Growth
- PVL N/A
- ATRA 475.53
- 52 Week Low
- PVL $1.03
- ATRA $5.01
- 52 Week High
- PVL $2.00
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- PVL 55.80
- ATRA 48.89
- Support Level
- PVL $1.72
- ATRA $7.51
- Resistance Level
- PVL $1.87
- ATRA $8.25
- Average True Range (ATR)
- PVL 0.09
- ATRA 0.53
- MACD
- PVL -0.01
- ATRA -0.13
- Stochastic Oscillator
- PVL 43.33
- ATRA 20.25
About PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production the sale of oil and natural gas production from primarily non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).